Acute Myeloid Leukemia

Why trials studying Acute Myeloid Leukemia stopped, in this sample of ClinicalTrials.gov.

51 stopped trials with a clear reason; 92% ended for non-scientific reasons.

Trials

• A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
  NCT07498465 · WITHDRAWN · logistics pi
  “Other - Protocol moved to Withdrawn”
• A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia
  NCT06903702 · WITHDRAWN · funding business
  “Lack of funding”
• A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
  NCT05521087 · WITHDRAWN · funding business
  “Business Decision”
• TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant
  NCT05968170 · WITHDRAWN · funding business
  “No funding available.”
• 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML
  NCT06626633 · SUSPENDED · funding business
  “Pharmaceutical Company withdrew support and investigational product”
• High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
  NCT05895201 · WITHDRAWN · logistics pi
  “PI has left IU with no plan to initiate study at IU”
• Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia
  NCT04185428 · TERMINATED · logistics pi
  “The PIs left the institution.”
• A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Venetoclax Through Chart Review
  NCT06362031 · WITHDRAWN · funding business
  “Strategic considerations”
• GM-CLAG in Relapsed/Refractory FLT3-mutated AML
  NCT05330377 · WITHDRAWN · funding business
  “Sponsor withdrew funding”
• Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
  NCT05246384 · WITHDRAWN · funding business
  “Change in development plan”
• Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML
  NCT05569512 · TERMINATED · logistics pi
  “On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.”
• A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
  NCT05607199 · TERMINATED · slow accrual
  “Patient recruitment problems.”
• ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)
  NCT05358808 · TERMINATED · slow accrual
  “The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January 2024.”
• Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission
  NCT04914676 · TERMINATED · slow accrual
  “PI decision to close study early due to limited data due to accrual goal not being met”
• Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
  NCT05066165 · TERMINATED · funding business
  “Pivoting to an allogeneic version of this program currently in preclinical development.”
• Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
  NCT04905407 · TERMINATED · funding business
  “As per sponsor decision, the study was terminated.”
• Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
  NCT04789408 · TERMINATED · futility
  “Study was terminated due to futility”
• Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
  NCT04964505 · TERMINATED · funding business
  “Sponsor decision”
• A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
  NCT04896112 · WITHDRAWN · funding business
  “sponsor decision”
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
  NCT04637009 · TERMINATED · funding business
  “termination due to portfolio prioritization”
• Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
  NCT04511130 · TERMINATED · manufacturing supply
  “Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long vein-to-vein manufacturing timeline of MT-401 after 38 participants received the autologous MT-401.”
• Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
  NCT04553692 · TERMINATED · funding business
  “Study terminated due strategic corporate pivot to focus on auto-immune indications”
• Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
  NCT04002115 · TERMINATED · slow accrual
  “terminated due to low accrual”
• A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia
  NCT04100330 · WITHDRAWN · logistics pi
  “Urgent shift among clinical sites toward efforts to combat COVID-19 pandemic;impacted feasibility of completing study within shelf-life of current IP supply”
• Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
  NCT04296214 · WITHDRAWN · slow accrual
  “Poor recruitment”
• Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
  NCT03728335 · SUSPENDED · slow accrual
  “Accrual goal met”
• Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
  NCT03066466 · WITHDRAWN · slow accrual
  “No participants were enrolled”
• Randomized Clinical Study Assessing Haplo vs. URD in AML
  NCT04067180 · TERMINATED · logistics pi
  “Delayed enrollment due to COVID-19 pandemic and other non-alterable world events, including war. The time elapsed when the study was paused has lowered the relevance of the study.”
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
  NCT03735446 · TERMINATED · funding business
  “Sponsor Decision”
• Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
  NCT03515707 · WITHDRAWN · logistics pi
  “PI recommended closure”
• Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy
  NCT03395873 · TERMINATED · regulatory
  “Recent FDA approval of a new drug for the same patient population”
• Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
  NCT03404193 · TERMINATED · slow accrual
  “\<75% participation”
• Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia
  NCT03318016 · TERMINATED · slow accrual
  “Low enrollment, University Scientific Review Committee required study closure.”
• Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
  NCT03126864 · TERMINATED · logistics pi
  “Terminated per the PI's request.”
• Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
  NCT03108911 · TERMINATED · logistics pi
  “limited resources”
• Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
  NCT03150004 · TERMINATED · funding business
  “No longer have funding support to complete the pharmacogenetics component.”
• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  NCT02942758 · TERMINATED · funding business
  “Due to financial reasons.”
• Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
  NCT03055286 · TERMINATED · funding business
  “business/strategic reason”
• Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
  NCT02676323 · TERMINATED · slow accrual
  “Slow accrual”
• A Study of PLX51107 in Advanced Malignancies
  NCT02683395 · TERMINATED · funding business
  “Business Decision”
• Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
  NCT02680951 · WITHDRAWN · slow accrual
  “Withdrawn due to lack of participants.”
• Observational Trial of a Therapeutic Platelet Transfusion Regimen
  NCT02276651 · TERMINATED · slow accrual
  “Insufficient recruitment”
• T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
  NCT01163201 · WITHDRAWN · other
  “Replaced by a new study”
• Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia
  NCT01960387 · TERMINATED · slow accrual
  “lack of accrual”
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
  NCT01908387 · TERMINATED · slow accrual
  “Due to Slow Accrual study was terminated.”
• Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia
  NCT01573247 · TERMINATED · safety
  “During the study two patients have experienced serious liver events related to AKN-028. The risk-benefit balance was judged to be negative.”
• ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
  NCT01478074 · WITHDRAWN · slow accrual
  “The treatment planned was determined to be of low feasibility as no subject was found eligible and able to enroll after screening over 30 subjects”
• Lenalidomide In Patients With Acute Myeloid Leukemia
  NCT00839059 · TERMINATED · other
  “Results of an interim analysis and a hardly ongoing enrolment in the last 10 months in all six participating centres”
• Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
  NCT00658411 · TERMINATED · slow accrual
  “Closed due to slow patient accrual”
• Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
  NCT00852709 · TERMINATED · slow accrual
  “Lack of accrual”
• Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
  NCT00480987 · TERMINATED · funding business
  “Lack of support.”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.